News | December 07, 2025
Paradigm Health to acquire Flatiron’s clinical research business
It's an acquisition that aims at forming one of the US's largest oncology trial networks
It's an acquisition that aims at forming one of the US's largest oncology trial networks
NAEH can cause heavy or abnormal bleeding and, if left untreated, may progress to uterine cancer
Terray and BMS aim to accelerate small molecule drug discovery by harnessing EMMI’s integrated experimental and AI capabilities
Senores Pharmaceuticals is poised to accelerate its presence in the Asia-Pacific region
O'Connor brings over 30 years of leadership experience in the biotechnology and oncology sectors
Here's a development that aims to keep your blood pressure in check. Literally!
The company is excluding data from the affected sites to maintain the study's integrity
Here's a new ray of hope for new hope for patients suffering from Meniere’s disease (MD) and sensorineural hearing loss
Suffering from acute migraine? You may soon bid adieu to the debilitating headache
Ilumya is the first IL-23 inhibitor to complete five years of study based on a pooled analysis of two Phase 3 efficacy and safety extension trials
Subscribe To Our Newsletter & Stay Updated
